We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The review will consider a range of options, including a full or partial separation of the consumer healthcare business from Pfizer through a spin-off, sale or other transaction